CrystalGenomics Promotes Global Partnering at 'Bio Europe 2020'

[Asia Economy Reporter Hyunseok Yoo] CrystalGenomics announced on the 27th that it will participate in ‘BIO-EUROPE 2020,’ one of the world's largest bio events.

The company is participating in ‘Bio Europe,’ held online from the 26th to the 29th (European time). It plans to conduct one-on-one partnering meetings for technology licensing negotiations of its pancreatic cancer treatment candidate Ivaltinostat, osteoarthritis new drug Aselex, and superbug eradication drug candidates with 27 major global pharmaceutical and biotech companies including AbbVie and Johnson & Johnson.

At this conference, several multinational pharmaceutical companies have shown interest and requested meetings regarding Crystal’s key pipeline, the pancreatic cancer drug candidate ‘Ivaltinostat,’ including its Phase 2 clinical data, future development directions, and the status of additional indications such as liver cancer. A CrystalGenomics official stated, “At this Bio Europe, we will especially introduce the technology and potential of Ivaltinostat to various global pharmaceutical companies,” adding, “This will provide an opportunity for more in-depth discussions to expand our global network.”

Meanwhile, ‘Bio Europe’ is Europe’s largest pharmaceutical and biotech event, celebrating its 26th edition this year, with over 3,000 pharmaceutical and biotech industry professionals from 60 countries worldwide participating to showcase the latest bio research achievements and bio development technologies.